<DOC>
	<DOCNO>NCT01376115</DOCNO>
	<brief_summary>To investigate safety efficacy Japanese subject treat nelarabine injection intravenous use clinical setting follow disease : 1 . T-cell acute lymphocytic leukemia ( T-ALL ) 2 . T-cell lymphoblastic lymphoma ( T-LBL ) Also , `` adverse event involve neurological disorder , hypotension , blood disorder detail '' investigate item particular concern . In addition , subject outcome ( alive dead ) one year start treatment also investigate .</brief_summary>
	<brief_title>Drug Use Investigation ARRANON G ( Nelarabine ) Injection 250mg</brief_title>
	<detailed_description />
	<criteria>Diagnosis Tcell acute lymphocytic leukemia ( TALL ) Tcell lymphoblastic lymphoma ( TLBL ) Subjects hypersensitivity nelarabine</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>